Pyoderma gangrenosum
Pyoderma gangrenosum é uma doença inflamatória rara da pele, em que pústulas ou nódulos dolorosos transformam‑se em úlceras que aumentam progressivamente. A doença não é infecciosa. Os tratamentos podem incluir corticosteroides, ciclosporina ou diversos anticorpos monoclonais. Embora possa afetar pessoas de qualquer idade, é mais comum entre os 40 e 50 anos.
☆ AI Dermatology — Free Service
Nos resultados do Stiftung Warentest de 2022 da Alemanha, a satisfação do consumidor com o ModelDerm foi apenas ligeiramente inferior do que com as consultas pagas de telemedicina.
Nos resultados do Stiftung Warentest de 2022 da Alemanha, a satisfação do consumidor com o ModelDerm foi apenas ligeiramente inferior do que com as consultas pagas de telemedicina.
Na perna de um paciente com colite ulcerosa.
relevance score : -100.0%
ReferencesPyoderma gangrenosum é uma doença rara da pele que causa úlceras dolorosas com bordas vermelhas ou arroxeadas. É classificada como uma doença inflamatória e faz parte de um grupo denominado dermatoses neutrofílicas. A causa do pyoderma gangrenosum é complexa, envolvendo alterações da imunidade inata e adaptativa em indivíduos geneticamente predispostos. Recentemente, os pesquisadores têm se concentrado no folículo capilar como um potencial ponto de partida da doença.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum é uma doença rara da pele que causa úlceras extremamente dolorosas. Embora ainda não compreendamos totalmente sua causa, sabemos que há um aumento da atividade de certas células do sistema imunológico. O tratamento da doença ainda não é fácil. Existem vários medicamentos que suprimem o sistema imunológico ou modificam sua atividade. Paralelamente, também nos concentramos no manejo das feridas e no controle da dor. Os corticosteroides e a ciclosporina são frequentemente a primeira escolha terapêutica, mas, recentemente, há mais pesquisas sobre o uso de terapias biológicas, como os inibidores do TNF‑α. Esses fármacos biológicos são cada vez mais preferidos, especialmente em pacientes com outras condições inflamatórias, e estão sendo empregados no início do curso da doença.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
